Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2021

01-01-2021 | Breast Cancer | Breast Oncology

Genetic Testing for Breast Cancer Patients: Is Everyone Who Needs a Test Getting a Test?

Authors: Danielle R. Heller, MD, MHS, Ann-Kristin U. Friedrich, MD, Brigid K. Killelea, MD, MPH, FACS

Published in: Annals of Surgical Oncology | Issue 1/2021

Login to get access

Excerpt

Genetic testing and counseling are important elements of comprehensive breast cancer care. Both positive and negative results have implications for patients diagnosed with cancer, unaffected mutation carriers, and untested family members. It is currently estimated that approximately 5–10% of all breast cancers are due to genetic mutations.1,2 Because breast cancer is the most common malignancy among women in the United States, with yearly incidence exceeding 250,000 cases, this proportion of gene-based breast cancer is significant.1 …
Literature
1.
2.
Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482–90.CrossRef
3.
Alberty-Oller JWS, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E. Adherence to NCCN guidelines for genetic testing in breast cancer patients: who are we missing? Ann Surg Oncol. 2020 (In press).
4.
Yang S, Axilbund JE, O’Leary E, et al. Underdiagnosis of hereditary breast and ovarian cancer in Medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25(10):2925–31.CrossRef
5.
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453–60.CrossRef
6.
7.
King M, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA. 2014;312(11):1091–2.CrossRef
8.
Copur MS, Jonglertham P, Zusag T. Should all patients with a diagnosis of breast cancer undergo expanded panel testing? J Clin Oncol. 2019;37(24):2175–6.CrossRef
Metadata
Title
Genetic Testing for Breast Cancer Patients: Is Everyone Who Needs a Test Getting a Test?
Authors
Danielle R. Heller, MD, MHS
Ann-Kristin U. Friedrich, MD
Brigid K. Killelea, MD, MPH, FACS
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09180-4

Other articles of this Issue 1/2021

Annals of Surgical Oncology 1/2021 Go to the issue

Thoracic Oncology

Prognostic Significance of Ground-Glass Opacity Components in 5-Year Survivors With Resected Lung Adenocarcinoma

Gastrointestinal Oncology

Impact of Perioperative Steroid Administration in Patients Undergoing Major Hepatectomy with Extrahepatic Bile Duct Resection: A Randomized Controlled Trial

Gynecologic Oncology

Editorial Response to Hepato-Biliary Disease Resection for Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction

Urologic Oncology

Evaluating the Oncological Outcomes of Pure Laparoscopic Radical Nephroureterectomy Performed for Upper-Tract Urothelial Carcinoma Patients: A Multicenter Cohort Study Adjusted by Propensity Score Matching

ASO Author Reflections

ASO Author Reflections: Ultra-Radical Resection in Ovarian Cancer: Where Are We and Where Are We Going?

Peritoneal Surface Malignancy

Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial